|Bid||57.06 x 1300|
|Ask||57.07 x 1200|
|Day's range||57.01 - 58.13|
|52-week range||56.66 - 69.75|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Earnings date||27 Oct 2021|
|Forward dividend & yield||1.96 (3.36%)|
|Ex-dividend date||30 Sep 2021|
|1y target est||79.36|
The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.
Since the consumer price index (an inflation indicator) rose 5.3% year over year in August, it's as important as ever to buy dividend stocks that can raise their dividend ahead of inflation to gain purchasing power. Here are two biotech stocks that not only can stay ahead of inflation through strong dividend increases but that are fairly priced and offer enticing 3% yields. Bristol Myers Squibb (NYSE: BMY) is the first biotech stock that investors should consider purchasing in October.
Bristol Myers Squibb (BMY) closed the most recent trading day at $58.36, moving +1.14% from the previous trading session.